JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

Search

Bio-Techne Corp

Gesloten

SectorGezondheidszorg

54.68 -0.33

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

53.84

Max

55.17

Belangrijke statistieken

By Trading Economics

Inkomsten

-12M

23M

Verkoop

19M

316M

K/W

Sectorgemiddelde

66.121

40.048

Dividendrendement

0.58

Winstmarge

7.144

Werknemers

3,100

EBITDA

-7.1M

68M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+19.33% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

0.58%

2.45%

Volgende Winsten

6 aug 2025

Volgende dividenddatum

29 aug 2025

Volgende Ex Dividend datum

18 aug 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-1.9B

8.6B

Vorige openingsprijs

55.01

Vorige sluitingsprijs

54.68

Nieuwssentiment

By Acuity

52%

48%

309 / 374 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Weak Bullish Evidence

Bio-Techne Corp Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

5 aug 2025, 23:11 UTC

Winsten

Australia's REA Hikes Dividend as Annual Profit Rises 23% -- Update

5 aug 2025, 22:45 UTC

Winsten

Australia's REA Hikes Dividend as Annual Profit Rises 23%

5 aug 2025, 22:39 UTC

Winsten

Great-West Lifeco Logs Lower 2Q Profit

5 aug 2025, 21:32 UTC

Winsten

Coupang Posts Higher 2Q Sales Due to Customer Growth

6 aug 2025, 00:00 UTC

Acquisities, Fusies, Overnames

NFL to Take 10% Stake in Disney's ESPN -- WSJ

6 aug 2025, 00:00 UTC

Acquisities, Fusies, Overnames

The NFL Is Taking a 10% Stake in Disney's ESPN -- WSJ

6 aug 2025, 00:00 UTC

Acquisities, Fusies, Overnames

Disney to Take Control of NFL Network as Part of Agreement -- WSJ

6 aug 2025, 00:00 UTC

Acquisities, Fusies, Overnames

Disney, NFL Strike Wide-Reaching Media-Asset Deal -- WSJ

5 aug 2025, 23:48 UTC

Marktinformatie

Nikkei May Decline Amid U.S. Economic Uncertainty -- Market Talk

5 aug 2025, 23:40 UTC

Marktinformatie

Gold Edges Higher, Supported by Fed Rate-Cut Hopes -- Market Talk

5 aug 2025, 23:19 UTC

Marktinformatie

Lindian Deal With Iluka Demonstrates Kangankunde Project Appeal -- Market Talk

5 aug 2025, 23:03 UTC

Marktinformatie
Winsten

Advanced Micro Devices' Data-Center Story Seen as Promising -- Market Talk

5 aug 2025, 22:22 UTC

Winsten

REA: Expectation of More Interest-Rate Cuts Likely to Support Buyer Demand>REA.AU

5 aug 2025, 22:21 UTC

Winsten

REA Expects FY26 Listing Volumes Broadly Flat on FY25>REA.AU

5 aug 2025, 22:20 UTC

Winsten

REA Expects September-Quarter Listings to Be Down on Year>REA.AU

5 aug 2025, 22:18 UTC

Winsten

REA July 2025 New Residential Listings Down 8% on Year>REA.AU

5 aug 2025, 22:17 UTC

Winsten

REA FY25 Australian Residential Listings Up 1% on Year>REA.AU

5 aug 2025, 22:17 UTC

Winsten

REA FY25 India Revenue A$129M Vs. A$103M>REA.AU

5 aug 2025, 22:16 UTC

Winsten

REA FY25 Core Australia Revenue A$1.54B Vs. A$1.35B>REA.AU

5 aug 2025, 22:16 UTC

Winsten

REA FY25 Core Operations Net Profit A$564.4M Vs. A$460.5M>REA.AU

5 aug 2025, 22:15 UTC

Winsten

REA Group FY25 Ebitda A$969.2M Vs. A$824.8M>REA.AU

5 aug 2025, 22:13 UTC

Winsten

REA Group Raises Dividend to A$1.38 Vs. A$1.02 >REA.AU

5 aug 2025, 22:13 UTC

Winsten

REA Group FY25 Rev A$1.67B Vs. A$1.45B >REA.AU

5 aug 2025, 22:12 UTC

Winsten

REA FY25 Core Operations Net Profit A$564.4M Vs, A$460.5M>REA.AU

5 aug 2025, 22:12 UTC

Winsten

REA Group FY25 Net A$677.9M Vs. Net A$302.8M >REA.AU

5 aug 2025, 21:58 UTC

Winsten

Novo Nordisk's Earnings Come After a Dramatic Guidance Cut. What to Look for Now. -- Barrons.com

5 aug 2025, 21:30 UTC

Winsten

AMD Gives a Strong Outlook. Why the Stock Is Falling. -- Barrons.com

5 aug 2025, 21:26 UTC

Winsten

AMD CEO Expects Embedded Segment to Return to Sequential Growth in Back Half of 2025

5 aug 2025, 21:23 UTC

Winsten

AMD CEO Sees Strong Customer Interest in MI400 Series for Large-Scale Deployments

5 aug 2025, 21:17 UTC

Winsten

AMD Expects Steep Production Ramp for MI350 Series in Back Half of Year, CEO Says

Peer Vergelijking

Prijswijziging

Bio-Techne Corp Prognose

Koersdoel

By TipRanks

19.33% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 65.5 USD  19.33%

Hoogste 75 USD

Laagste 58 USD

Gebaseerd op 12 Wall Street-analisten die 12-maands prijsdoelen bieden voor Bio-Techne Corp - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

12 ratings

9

Buy

3

Hold

0

Sell

Technische score

By Trading Central

49.67 / 50.24Steun & Weerstand

Korte Termijn

Weak Bullish Evidence

Gemiddeld Termijn

Weak Bullish Evidence

Lange Termijn

Strong Bearish Evidence

Sentiment

By Acuity

309 / 374 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Bio-Techne Corp

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company has strategic partnership with ALZpath, Inc. to accelerate breakthroughs in neurodegenerative disease research and treatment, including Alzheimer's disease. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.